Chen et al have reported a metastatic non-small cell lung cancer patient who developed MN after ICIs therapy.[9] Kim have described a case of nephrotic syndrome relapse in a patient with a history of MN during PD-L1 inhibitor durvalumab therapy for non-small cell lung cancer.[10] These findings indicate that there is a risk of M-MN patients with MN relapse or nephrotic syndrome after ICIs therapy for cancers, which should be noted in the clinical practice of M-MN. This evidence concerns the gene CD274 and cancer.